Biond­Vax stock im­plodes af­ter a big PhI­II gam­ble for its uni­ver­sal flu vac­cine fails

Af­ter fly­ing high on Wall Street for the last few months of a pan­dem­ic, Biond­Vax’s stock and dreams of get­ting ap­proval for its uni­ver­sal flu vac­cine hit the wind­shield.

The Jerusalem-based biotech an­nounced on Fri­day that its on­ly clin­i­cal can­di­date, M-001, failed both pri­ma­ry and sec­ondary end­points in a Phase III study. There was no sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in re­duc­tion of flu ill­ness and sever­i­ty be­tween the vac­cine and place­bo groups, ac­cord­ing to the com­pa­ny. The vac­cine did prove safe, if in­ef­fec­tive, Biond­Vax said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER